Regeneron Pharmaceuticals Inc

Regeneron stock could face more obstacles. Will the omicron variant of the COVID-19 virus redefine the pandemic's trajectory? What's the forecast for the stock?

The FDA authorized a COVID-19 drug cocktail from Regeneron, but that doesn't mean it's better than the vaccine.

the U.S. Food and Drug Administration accepted the filing of a supplemental Biologics License Application for Bristol-Myers Squibb’s Opdivo.

In 2016, Regeneron expects to face increased competition from Roche Holding’s Lucentis (Ranibizumab) and Avastin (Bevacizumab) for Eylea.

Regeneron Pharmaceuticals (REGN) depends heavily upon its key drug, Eylea, which recorded global sales of $4.1 billion during fiscal 2015.

23.1% of analysts gave United Therapeutics (UTHR) a “buy” recommendation while 69.2% of analysts rated the company a “hold.”

Sanofi and Regeneron are conducting clinical studies for the treatment of a range of type 2 inflammation conditions with Dupixent.

Roche Holding has agreed to help develop and distribute an experimental COVID-19 drug in partnership with Regeneron Pharmaceuticals.

Wall Street analysts expect a potential upside of 6.79% for Regeneron Pharmaceuticals based on the company’s closing price on March 27.

On September 15, Sanofi and Regeneron announced Phase 3 data results for Dupixent for the treatment of moderate-to-severe atopic dermatitis.

In January 2017, Regeneron Pharmaceuticals’ (REGN) Kevzara was approved in Canada for the treatment of patients with active rheumatoid arthritis.

Analysts expect Incyte Corporation’s revenue to rise ~26.7% to $413.8 million in 4Q17 compared to $326.5 million in 4Q16.

According to a Monte Carlo simulation performed at Harvard, it’s estimated that 5.0 million patients in the United States stand to benefit from PCSK9 inhibitor therapy.

In 1H17, Novartis’s (NVS) Lucentis reported revenues of around $922 million, which is a ~1% decline on a year-over-year (or YoY) basis.

Regeneron and Sanofi have submitted an application seeking regulatory approval for Kevzara in Japan.

In June 2017 and July 2017, healthcare providers wrote prescriptions for Regeneron (REGN) and Sanofi’s (SNY) Dupixent for 750 new patients on a weekly basis.

In 1H17, Eylea’s total sales rose 10% on a year-over-year basis.

Ionis Pharmaceuticals (IONS) has been one of the leading pharmaceutical companies in the RNA-targeted therapeutic space for over 26 years.

In March 2017, the FDA approved Regeneron and Sanofi’s Dupixent injection for the treatment of adult individuals with moderate to severe atopic dermatitis.

Regeneron (REGN) has obtained positive results from its Phase 2 proof-of-concept study evaluating Dupixent in eosinophilic esophagitis.

Regeneron plans to discuss Dupixent’s innovative mechanism-based treatment approach with regulatory authorities.

After Dupixent’s commercial launch, Regeneron has been involved in creating awareness for the drug among physicians who have been treating AD patients.

In 1Q17, Amgen’s (AMGN) Repatha witnessed quarter-over-quarter growth in sales volume of ~14% and 28% in the US and Europe, respectively.

Enbrel, Neulasta, and Epogen are among Amgen’s (AMGN) major revenue-generating drugs, each with annual sales in excess of $1 billion. Enbrel and Neulasta together accounted for ~46% of Amgen’s 2016 revenues.

On March 28, 2017, the FDA approved Regeneron (REGN) and Sanofi’s (SNY) Dupixent for the treatment of patients with moderate-to-severe eczema or atopic dermatitis (or AD).

In addition to being explored as a monotherapy for AD (atopic dermatitis), Regeneron and Sanofi are also researching Dupixent for other indications.

In Phase 3 trials, SOLO 1 and SOLO 2, Regeneron (REGN) and Sanofi (SNY) tested the efficacy of an investigational therapy, Dupixent, compared to a placebo.

Existing treatment options for AD aren’t tolerated well by the entire patient population. Dupixent might become a preferred regimen in the future.

LixiLan indicated for type 2 diabetes is a combination of Lantus and lixisenatide. Lantus is Sanofi’s most frequently prescribed diabetes drug.

Alexion (ALXN) has been serving the atypical hemolytic uremic syndrome, or aHUS, market for the past five years.

Dupilumab has a breakthrough therapy designation from the FDA for the indication of moderate-to-severe atopic dermatitis in adults.

Regeneron’s (REGN) robust pipeline consists of 13 molecules in various phases of development. Sarilumab is under review with the FDA.

Vertex is trying to expand its product base beyond cystic fibrosis. It holds molecules in the oncology, respiratory, pain, spinal cord, and influenza spaces.

Vyvanse is Shire’s leading ADHD drug, constituting 80% of the company’s ADHD portfolio. In fiscal 2015, Vyvanse earned the company $1.7 billion.

Regeneron Pharmaceuticals (REGN) earns revenue from net product sales, collaboration, and technology licenses.

Kuvan, with the active ingredient sapropterin dihydrochloride, is effective in reducing blood phenylalanine levels in PKU (or phenylketonuria) patients.

Lesinurad, originally developed by Ardea Biosciences, was acquired by AstraZeneca through the acquisition of Ardea in June 2012. It works to reduce the uric acid levels in gout patients.

On November 24, Novartis announced that the European Commission had approved Entresto as a therapy for adult patients suffering from symptomatic chronic heart failure with reduced ejection fraction.

Alexion Pharmaceuticals is actively involved in expanding the approved labels for its flagship product Soliris.

Regeneron generates revenues in three ways: product sales, revenues earned through collaboration arrangements, and revenues earned from licensing proprietary technology.

With a market capitalization of $50.7 billion, Regeneron is one of the country’s major biotechnology companies. Its products and pipeline candidates focus on cancer, eye diseases, and cardiovascular diseases.

In the early stages of their life cycles, most biotechnology companies are financed by venture capital, which typically comes from wealthy investors who invest in startup companies.

A drug approval process is required in order for a new drug to enter the market. Companies with new drugs in later stages of the approval process are more likely to earn a positive cash flow in the next few years.

The type of business model a biotechnology company selects depends on technical capability, availability of resources, and competition in the industry.

Biotechnology is simply ‘technology based on biology.’ The biotechnology industry includes food technology, genetic research, healthcare, and environmental technology.